The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10080
Phase I Study of Recombinant Interleukin 15 in Combination with Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers
National Cancer Institute Developmental Therapeutics Clinic
Chen, A P
(240) 781-3320
Phase I – ABTC-1604
Phase 0/I Study of AMG 232 Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Adult Brain Tumor Consortium
Alexander, Brian Michael
(617) 732-7560
Phase I – AMC-S007
Longitudinal Quality of Life Study Among Participants with AIDS-Associated Kaposi Sarcoma
Bugando Medical Centre, in Mwanza, Tanzania
AIDS Malignancy Consortium
Schroeder, Kristin Marie
(919) 668-6288
Phase II – 10139
A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib Versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Azad, Nilofer Saba
(410) 614-9169
Phase II – EA5161
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
ECOG-ACRIN Cancer Research Group
Leal, Ticiana A.
(608) 263-9063
Phase II – EA8153
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
ECOG-ACRIN Cancer Research Group
Kyriakopoulos, Christos
(608) 263-0786
Phase II/III – NRG-HN004
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
NRG Oncology
Mell, Loren K.
(858) 246-0471
Phase II/III – S1612
A Randomized Phase II/III Trial of “Novel Therapeutics” Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older (LEAP: Less-Intense AML Platform Trial)
SWOG
Michaelis, Laura Christian
(414) 805-1118
Phase Other – AALL17B7-Q
Germline TP53 and ETV6 Mutations in Acute Lymphoblastic Leukemia
Children’s Oncology Group
Yang, Jun J.
(901) 595-2517
Phase Other – AALL17B8-Q
Dissecting the Prognostic Impact of the Pediatric B-ALL Immune Microenvironment Using Single-Cell Approaches
Children’s Oncology Group
Carroll, William L.
(212) 263-9947
Phase Other – WF-30917CD
A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
Wake Forest NCORP Research Base
Danhauer, Suzanne C.
(336) 716-7980
